Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 61% Improvement Relative Risk Recovery time 65% Guérin et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ+AZ beneficial for COVID-19? Retrospective 88 patients in France Faster recovery with HCQ+AZ (p=0.0001) Guérin et al., Asian J. Medicine and Health, Jul.., doi:10.9734/ajmah/2020/v18i730224 Favors HCQ Favors control
Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
Guérin et al., Asian J. Medicine and Health, July 15, 2020, doi:10.9734/ajmah/2020/v18i730224 (date from earlier preprint)
Guérin et al., Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19, Asian J. Medicine and Health, July 15, 2020, doi:10.9734/ajmah/2020/v18i730224 (date from earlier preprint)
May 2020   Source   PDF  
  All Studies   Meta
Mean clinical recovery time reduced from 26 days (SOC) to 9 days, p<0.0001 (HCQ+AZ) or 13 days, p<0.0001 (AZ). No cardiac toxicity. Small retrospective study of 88 patients with case control analysis with matched patients.
risk of death, 61.4% lower, RR 0.39, p = 1.00, treatment 0 of 20 (0.0%), control 1 of 34 (2.9%), NNT 34, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
recovery time, 65.0% lower, relative time 0.35, p < 0.001, treatment 20, control 34.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Guérin et al., 31 May 2020, retrospective, France, peer-reviewed, 8 authors, dosage 600mg days 1-10, 7-10 days, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Asian Journal of Medicine and Health 18(7): 45-55, 2020; Article no.AJMAH.59198 ISSN: 2456-8414 Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 Violaine Guérin1*, Pierre Lévy2, Jean-Louis Thomas1, Thierry Lardenois1, Philippe Lacrosse1, Emmanuel Sarrazin1, Natacha Regensberg-de Andreis1 and Martine Wonner1 1 Collectif Laissons Les Médecins Prescrire, France. Département de Santé Publique, Institut Pierre-Louis de Santé Publique (INSERM UMR S 1136, EPAR Team), Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, 75020 Paris, France. 2 Authors’ contributions This work was carried out in collaboration among all authors. Authors VG and JLT designed the study and wrote the first draft of the manuscript. Authors VG, TL, ES, NRA, P. Lacrosse and MW followed the patients. Author P. Lévy performed the statistical analysis. All authors read and approved the final manuscript. Article Information DOI: 10.9734/AJMAH/2020/v18i730224 Editor(s): (1) Dr. John K. Triantafillidis, Iasi University of Medicine and Pharmacy, Romania and IASO General Hospital, Greece. (2) Darko Nozic, University of Belgrade, Serbia. Reviewers: (1) Malangori Abdulgani Parande, Byramjee Jeejeebhoy Government Medical College (BJGMC), India. (2) Olga Rukhmakova, National University of Pharmacy, Ukraine. Complete Peer review History: Original Research Article Received 26 June 2020 Accepted 14 July 2020 Published 15 July 2020 ABSTRACT Aims: The challenge regarding COVID-19 is to prevent complications and fatal evolution. Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro. We aimed to assess the efficacy and safety of AZM alone or combined to HCQ, prescribed, at an early stage, in patients with Covid-19, in a primary care setting. Study Design: Retrospective observational study. Place and Duration of Study: Patients have been followed by private practitioners in France, between March and April 2020. Methodology: Eighty-eight patients received either no or a symptomatic treatment (NST) (n=34) or AZM alone (n=34) or AZM+HCQ (n=20). The efficacy end point was the time to clinical recovery _____________________________________________________________________________________________________ *Corresponding author: E-mail:; Guérin et al.; AJMAH, 18(7): 45-55, 2020; Article no.AJMAH.59198 and the safety end point was the occurrence of cardiovascular events. To improve the evidence level, a case-control analysis was performed on a sample of 57 patients (19/group) matched for age, sex and BMI. Results: The mean (SD) times to achieve clinical recovery were respectively 25.8 days (11.1), 12.9 days (13.4) and 9.2 days (9.3), showing a statistically significant difference between NST and AZM alone (p<0.0001) or AZM+HCQ (p<0.0001). The statistical difference between NST and AZM was confirmed (p=0.0149) as well as the difference with AZM+HCQ (p=0.0002). No cardiac toxicity was recorded in any patient. No statistical difference was shown between AZM and AZM+HCQ groups, although the dual therapy tended to be more effective in patients over 50 years, based on an analysis using the cox model. Conclusion: AZM and AZM+HCQ favourably impacted the course of the disease. We need trials, ideally prospective/double blind, to show if a statistical difference can be evidenced with a broader group, and clarify the..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop